532 results about "Dermatitis repens" patented technology

The present invention provides non-invasive methods for detecting, monitoring, and diagnosing skin disease and pathological skin states such as irritated skin and psoriasis. The methods include using tape stripping to analyze expression in epidermal samples, of one or more skin markers. In illustrative examples, the tape stripping is performed using pliable tape that has a rubber adhesive. Furthermore, the present invention provides methods for predicting and monitoring response to therapy for a skin disease, such as psoriasis or dermatitis. Finally, the methods can include the use of a micro array.

The invention discloses a hyaluronic acid dressing and a preparation method thereof. The dressing comprises the following components in percentage by mass: 0.01-0.3% of medium-molecular-weight hyaluronic acid, 0.01-0.5% of small-molecular-weight hyaluronic acid, 0.03-1% of allantoin, 0.1-1% of Carbomer, 2-5% of sorbitol, 0.2-1% of trehalose, 0.7-2.5% of witch hazel distillate, 0.1-0.5% of D-panthenol, 0.05-0.15% of alpha-bisabolol, 0.2-1.0% of oat glucan, 2-10% of glycerinum, 0.06-1% of water-soluble silicon wax, 0.05-0.9% of an antalkali, 0.004-0.2% of 2-methyl-4-isothiazoline-3-one, 0.05-0.4% of phenoxyethanol, 0.005-0.05% of pentanediol, 0.01-0.06% of octylene glycol, 0.025-0.5% of methylparaben and the balance of water. The dressing disclosed by the invention is capable of permeating into the deep layers of the skin to remove excessive free radicals, promoting the generations of blood vessels, and accelerating the union of wounds, in particular, acnes, eczematous dermatitis, photorejuvenation postoperation repair and the like.

The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR⁴, C═O, C═S, OP(O)(O), P═O, CH₂, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C═O, O, S, CH₂, or NR⁵; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.

The invention is a functional skin care product containing purslane extractive. Raw materials of the functional skin care product include, by weight, 10 parts of purslane extractive, 1-2 parts of Prinsepia utilis rogle oil, 2-5 parts of glycerol, 0.3-0.5 parts of crylic acid (ester) /C10-30 alkanol acrylate cross-linked polymer, 2-3 parts of 1,2-pentanediol, 1-5 parts of synthesized squalane, 1-2 parts of tocopheryl acetate, 2-3 parts of cetostearyl alcohol, 0.1-0.2 part of allantoin, 0.3-0.8 part of sodium hyaluronate, 3-5 parts of Butyrospermum parkii butter, and 100 parts of deionized water. Or the Prinsepia utilis rogle oil and the Butyrospermum parkii butter are not added. By the aid of animal experiments, namely, mouse auricle swelling models due to dimethlbenzene, the functional skin care product containing purslane extractive is fine in anti-inflammation and anti-allergy effects, mild in nature and fine in safety, and is free of toxic reaction and anaphylaxis. The functional skin care product has an adjuvant therapy function to skin barrier recovery of common discosmetic dermatosis such as hormone dependent dermatitis and acne, and is fine in curative effect and safety.

A cosmetic treatment method, and a device therefor, are provided that allow for cosmetic treatment of cosmetic disorders, caused by chronological age, environmental factors, changes in physiological functions of skin, such as psoriasis, dermatitis, acne, cellulites, and viral and/or bacteriological attacks. The device comprises a nitric oxide (NO) eluting polymer arranged to contact the area to be cosmetically treated, such that a cosmetic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area. The nitric oxide (NO) eluting polymer is integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of said cosmetic dosage of nitric oxide (NO). Furthermore, a manufacturing method for said device is provided.

The present invention provides unique, efficacious, inexpensive, safe, reliable, convenient, minimally bitter, skin protecting and penetrating, easy-to-administer base compositions and active agent-containing compositions, such as those including hydrocortisone, and related production and topical application methods, for treating the skin of mammals for a wide variety of different dermatologic conditions, disorders and diseases, such as inflammation, redness, cracking, insect bites, dryness, allergic reactions, trauma, irritant dermatitis, perleche, contact dermatitis, psoriasis, eczema, seborrheic dermatitis, acne excoriate, xerosis, eczema craquele, stasis dermatitis, disease related conditions and dryness from medications such as isotretinoin, acitretin and lipid lowering agents. This is effected by topically administering, or otherwise applying, effective amounts of the compositions thereto in forms that not only address the skin and mucosa of the mouth and lips, but also of the rest of the body and, in particular, areas where other topical balms containing hydrocortisone and other active ingredients have not been developed or marketed. Additionally, the flavoring addition to this product, and the base wherein the active ingredient(s) reside, affords a significantly better tasting, and less bitter, composition, thereby allowing a more pleasant experience and better compliance by patients. Larger sized stick formulation(s) allow for more applicability of the product, and more usefulness thereof, in various areas, and mucosal skin, of the body. The compositions include a unique formulation of FANCOL VB, Natunola Castor 1023, Finsolv TN, bees wax and, optionally, one or a plurality of plant or plant seed oils, fatty alcohols, fats and flavorings, in desirable weight percents thereof, in various forms, and preferably in the form of a solid roll-on stick present in a variety of sizes.

The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and/or an inhibitor of the Na_x/SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Na_x Prss8, IL-1β, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.

The invention relates to a polycyclic derivative inhibitor as well as a preparation method and application thereof. Particularly, the invention relates to a compound represented by a general formula,the preparation method of the compound, a pharmaceutical composition containing the compound and the application of the compound as an intracellular non-receptor tyrosine kinase to mediation of signaltransduction and activation of various cell factors. The compound plays a key role in the biological process of participating in immunoregulation, immune cell proliferation and the like, is closely related to various inflammatory diseases such as rheumatoid arthritis, dermatitis, psoriasis, inflammatory bowel diseases (ulcerative colitis and Crohn's disease) and the like, and has the same substituent groups in the following general formula (I) as defined in the specification.

The invention relates to a therapeutic agent for fungal dermatitis, containing luliconazole or a pharmaceutically acceptable salt thereof as an active ingredient, and a composition for the treatment of fungal dermatitis, containing luliconazole or lanoconazole in a substantially dissolved state as an active ingredient.

The medicine for treating dermatosis is prepared with five kinds of Chinese medicinal materials, including paris rhizome, Chinese goldthread, skullcap root, rhubarb and gromwell, and the recipe may have other four kinds of Chinese medicinal materials in certain weight proportion. It may be medicine powder, decoction, ointment or paste. The medicine has the functions of clearing away heat and toxic material, promoting blood circulation to disperse blood clots, eliminating swelling and pain, etc. and may be used in treating acne, bedsore, boil, eczema, dermatitis, burns, scalds and other dermatosis. It has the advantages of high healing effect, fast acting, no irritation to skin, etc.

The invention discloses a medical skin care agent and a preparation method thereof, wherein, the medical skin care agent provided in the invention mainly comprises chitosan or derivatives thereof, a gelling agent and preservative. Specifically, the gelling agent is advantaged in that: ceramide, a mixture of sphingolipids and phospholipids, ceramide analogue and the like are used to form a layered-structure gel phase structure which is similar to skin lipoid structure and capable of enhancing the lipoid structure of the skin itself, thereby realizing the function of repairing skin barrier; due to the adding of the chitosan or the derivatives thereof in the medical skin care agent, the medical skin care agent is provided with broad-spectrum anti-microbial property and can effectively repair common skin inflammation of redness, swelling, peeling, itching and the like for dry, damaged and sensitive skin, thereby realizing anti-microbial function and anti-inflammation function in medical skin care.

The invention relates to the technical field of antibodies, and especially relates to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody can be specifically combined with hTSLP, has high affinity, and can effectively inhibit the combination of TSLP and a receptor thereof so as to inhibit activation of a downstream signal path and activation of immune cells by TSLP. The TSLP antibody has great significance in detection of the content of hTSLP and allergic asthma, and diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic nasosinusitis, eosinophilic granulocytic esophagitis, allergic conjunctivitis, inflammatory bowel disease or atopic dermatitis.

The invention provides a pharmaceutical preparation for treating skin diseases and a preparation method thereof. It is mainly prepared from the raw materials of S. Some or all of the Kochia scoparia medicinal materials are used in combination. Compared with the prior art, the formula provided by the present invention can be prepared into oral preparations or external preparations according to the conventional preparation process. Sexual skin diseases have a good curative effect, the total effective rate can reach more than 95%, and it is safe to use, has no toxic and side effects, and does not produce drug resistance. It is a safe, effective and quality-controllable treatment for itchy skin diseases. New medicine of traditional Chinese medicine.

The invention relates to lithospermum oil and a preparation method thereof. The lithospermum oil is formed by lithospermum and sesame oil or rap oil according to the component ratio of 1 to 3, is prepared by the method of cleaning and chopping, mixing and soaking, waterproof cooking, aseptic filtration and storage for standby, solves the problem that no economic, applicable, convenient and effective Chinese medicine preparation is used for treating disposable diaper dermatitis of infants, does not need to be orally taken, is economic and convenient, has no adverse reaction and side effect, has ideal treatment effect, is currently the best Chinese medicine preparation for treating disposable diaper dermatitis of the infants, and is also suitable for treating diseases such as edema pain, pimple, tetter, dermatitis, exfoliative inflammation of lips, anaphylactoid purpura and so on.

The present invention generally relates to topical compositions, and particularly to a topical ointment for treatment of skin disorders and methods of use thereof The present invention recognizes that treatment of certain skin disorders can be more efficient, safe, and rapid-acting with few or no side effects. The present invention is particularly adaptable for treatment of a variety of skin disorders, such as for example, dermatitis (eczema), psoriasis and other forms of immuno-dysfunctional dermatitis. The present invention can be combined as supplement treatment to many available over-the counter and/or prescriptive products for treatment of skin disorders.

The invention provides application of a panaxadiol saponins fraction in preparing a medicine for preventing dermatitis and scar and a health-care cosmetic. The panaxadiol saponins fraction comprises the following main constituents: ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc and ginsenoside Rd. The medicine or the cosmetic is prepared from active constituents in the single panaxadiol saponins fraction or/and other medicines together and a pharmaceutically acceptable or cosmetic acceptable carrier. The medicine or the cosmetic is prepared by utilizing raw materials: ginseng rhizome medicinal materials, American ginseng rhizome medicinal materials, ginseng stem leaf medicinal materials, American ginseng leaf medicinal materials and total extractives or total saponins of the ginseng rhizome medicinal materials, the American ginseng rhizome medicinal materials, the ginseng stem leaf medicinal materials and American ginseng leaf medicinal materials through a chromatographic separation and purification method combining macroporous resin column chromatography and octadecylsilane chemically bonded silica column chromatography. The scar can be prevented from forming while the tissue regeneration and repair are promoted by the medicine or the cosmetic. Compared with glucocorticoids, cellular immunity is integrally regulated, the drug action is stable after the medicine is suspended, and the drug action advantage is obvious. The medicine or the health-care cosmetic is highly safe. The structural formula of panaxadiol saponins is shown in the specification.

The invention discloses an oil-in-water type compound geranium oil nanometer milk composition. The particle diameter of the composition is 1-100nm. The composite is composed of the following raw materials by weight percentage: 28.5%-42.1% of a surfactant, 0.01%-5.6% of geranium oil, 0.01%-4.6% of evening primrose seed oil, 0.01%-2.8% of cade oil, 0.01%-1.4% of orange flower oil, 0.01%-1.4% of lavender oil and balanced distilled water. The sum of the mass percentage of the raw materials is 100%. The oil-in-water type compound geranium oil nanometer milk composite can obviously treat dermatitis, eczema and pale scar and can alleviate premenstrual syndrome to different degrees, improves biological utilization degree of essential oil, enhances pharmacological activity of the essential oil, enables the essential oil to be strong in permeability, good in stability, durable in acting time and obvious in effect, and has wide market prospect in the field of medicines.

The invention discloses a loratadine oral quickly-soluble film and a preparation method thereof. By controlling parameters such as particle size of a loratadine drug, proportion of a film-forming material, content of water of a film product and the like, the product dissolution is improved, the bioavailability can be improved, the preparation can effectively prevent and cure such as allergic rhinitis, chronic idiopathic urticaria, allergic asthma, atopic dermatitis and associated symptoms caused by allergy such as skin diseases (eczema, dermatitis, pruritus cutanea), and the drug effect can be sufficiently realized. The loratadine oral quickly-soluble film does not need water, can be rapidly dissolved in the oral cavity and is convenient to take by patients and particularly suitable for the old people and children patients; moreover, the loratadine oral quickly-soluble film has characteristics of high dispersity, rapidness in absorption, fastness in effect, favorability for improving the bioavailability, and the like.

The invention discloses new application of arginine, which is the application of arginine or a pharmaceutically acceptable salt, an ester or a mixture of the salt and the ester in preparing topical pharmaceutic preparations with at least one of the following effects: (1) treating and/or facilitating wound healing, and (2) reducing scar formation. Results in pharmacodynamics experiments show that the external use of L-arginine can remarkably facilitate trauma healing of rat skin as well as reduce the area of a wound scar. Arginine not only can be used for treatment and healing of traumas but also can be used for other skin diseases, including a pressure ulcer (bedsore), skin injuries caused by dermatitis, scald, burn and the like.